S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   383.05 (+0.80%)
AAPL   152.24 (+2.28%)
MSFT   324.32 (+0.36%)
FB   315.75 (+1.13%)
GOOGL   2,906.59 (-0.61%)
TSLA   1,068.28 (+2.93%)
AMZN   3,432.59 (+1.18%)
NVDA   248.36 (+1.57%)
BABA   169.79 (+0.33%)
NIO   40.72 (+3.59%)
CGC   12.94 (+1.25%)
GE   105.25 (+1.35%)
AMD   120.64 (-1.34%)
MU   69.21 (+1.42%)
T   25.54 (+1.92%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.20 (+0.54%)
BA   207.83 (+0.59%)
AMC   35.24 (+1.38%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   383.05 (+0.80%)
AAPL   152.24 (+2.28%)
MSFT   324.32 (+0.36%)
FB   315.75 (+1.13%)
GOOGL   2,906.59 (-0.61%)
TSLA   1,068.28 (+2.93%)
AMZN   3,432.59 (+1.18%)
NVDA   248.36 (+1.57%)
BABA   169.79 (+0.33%)
NIO   40.72 (+3.59%)
CGC   12.94 (+1.25%)
GE   105.25 (+1.35%)
AMD   120.64 (-1.34%)
MU   69.21 (+1.42%)
T   25.54 (+1.92%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.20 (+0.54%)
BA   207.83 (+0.59%)
AMC   35.24 (+1.38%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   383.05 (+0.80%)
AAPL   152.24 (+2.28%)
MSFT   324.32 (+0.36%)
FB   315.75 (+1.13%)
GOOGL   2,906.59 (-0.61%)
TSLA   1,068.28 (+2.93%)
AMZN   3,432.59 (+1.18%)
NVDA   248.36 (+1.57%)
BABA   169.79 (+0.33%)
NIO   40.72 (+3.59%)
CGC   12.94 (+1.25%)
GE   105.25 (+1.35%)
AMD   120.64 (-1.34%)
MU   69.21 (+1.42%)
T   25.54 (+1.92%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.20 (+0.54%)
BA   207.83 (+0.59%)
AMC   35.24 (+1.38%)
S&P 500   4,596.42 (+0.98%)
DOW   35,730.48 (+0.68%)
QQQ   383.05 (+0.80%)
AAPL   152.24 (+2.28%)
MSFT   324.32 (+0.36%)
FB   315.75 (+1.13%)
GOOGL   2,906.59 (-0.61%)
TSLA   1,068.28 (+2.93%)
AMZN   3,432.59 (+1.18%)
NVDA   248.36 (+1.57%)
BABA   169.79 (+0.33%)
NIO   40.72 (+3.59%)
CGC   12.94 (+1.25%)
GE   105.25 (+1.35%)
AMD   120.64 (-1.34%)
MU   69.21 (+1.42%)
T   25.54 (+1.92%)
F   16.86 (+8.70%)
ACB   6.88 (+0.58%)
DIS   169.68 (+0.08%)
PFE   43.20 (+0.54%)
BA   207.83 (+0.59%)
AMC   35.24 (+1.38%)
NYSE:RMD

ResMed Stock Forecast, Price & News

$268.72
+0.60 (+0.22 %)
(As of 10/28/2021 03:59 PM ET)
Add
Compare
Today's Range
$267.11
$275.54
50-Day Range
$251.62
$297.36
52-Week Range
$177.70
$301.34
Volume
37,599 shs
Average Volume
594,922 shs
Market Capitalization
$39.15 billion
P/E Ratio
82.94
Dividend Yield
0.63%
Beta
0.3
30 days | 90 days | 365 days | Advanced Chart
Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.


ResMed logo

About ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the following segments: Sleep and Respiratory Care, and Software as a Service. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment engages in the supply of business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
7,770
Year Founded
1989

Sales & Book Value

Annual Sales
$3.20 billion
Cash Flow
$6.07 per share
Book Value
$19.83 per share

Profitability

Net Income
$474.51 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$39.15 billion
Next Earnings Date
10/28/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

700th out of 1,374 stocks

Surgical & Medical Instruments Industry

75th out of 125 stocks

Analyst Opinion: 1.1Community Rank: 3.5Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view top-rated stocks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for ResMed
.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, October 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13723324".

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its earnings results on Thursday, August, 5th. The medical equipment provider reported $1.35 EPS for the quarter, topping analysts' consensus estimates of $1.25 by $0.10. The medical equipment provider earned $876.10 million during the quarter, compared to analysts' expectations of $781.10 million. ResMed had a trailing twelve-month return on equity of 28.03% and a net margin of 14.84%. During the same period in the previous year, the company earned $1.33 EPS.
View ResMed's earnings history
.

How has ResMed's stock price been impacted by COVID-19?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RMD shares have increased by 74.9% and is now trading at $268.67.
View which stocks have been most impacted by COVID-19
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, August 5th. Investors of record on Thursday, August 19th will be given a dividend of $0.42 per share on Thursday, September 23rd. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Wednesday, August 18th. This is a boost from ResMed's previous quarterly dividend of $0.39.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.63%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 25.19% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

12 equities research analysts have issued 1-year price targets for ResMed's shares. Their forecasts range from $210.00 to $270.00. On average, they anticipate ResMed's share price to reach $241.50 in the next year. This suggests that the stock has a possible downside of 10.1%.
View analysts' price targets for ResMed
or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Mick Farrell, Chief Executive Officer & Director
  • Rob Douglas, President & Chief Operating Officer
  • Brett A. Sandercock, Chief Financial Officer
  • Carlos M. Nunez, Chief Medical Officer
  • Bobby Ghoshal, Chief Technology Officer & President-SaaS Business

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (1.96%), Sumitomo Mitsui Trust Holdings Inc. (0.68%), Welch & Forbes LLC (0.21%), Stephens Investment Management Group LLC (0.18%), New York State Teachers Retirement System (0.12%) and Capital Investment Services of America Inc. (0.09%). Company insiders that own ResMed stock include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Stephens Investment Management Group LLC, Sumitomo Mitsui Trust Holdings Inc., Nisa Investment Advisors LLC, Frontier Capital Management Co. LLC, Crossmark Global Holdings Inc., Capital Investment Services of America Inc., and New York State Teachers Retirement System. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which major investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Railway Pension Investments Ltd, Tandem Investment Advisors Inc., Advisors Preferred LLC, WINTON GROUP Ltd, FNY Investment Advisers LLC, Assenagon Asset Management S.A., and Pensionfund DSM Netherlands.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $268.67.

How much money does ResMed make?

ResMed has a market capitalization of $39.14 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.33 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,770 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.